A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: Comparison with results obtained by other published algorithms

European Journal of Clinical Pharmacology

Volumn 68, Issue 8, 2012, Pages 1167-1174

  Cini, Michela ^a   Legnani, Cristina ^a   Cosmi, Benilde ^a   Guazzaloca, Giuliana ^a   Valdrè, Lelia ^a   Frascaro, Mirella ^a   Palareti, Gualtiero ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

CYP2C9; Pharmacogenetic algorithm; VKORC1; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; DNA; WARFARIN;

ACCURACY; ALGORITHM; ANALYTICAL ERROR; ANTICOAGULANT THERAPY; ARTICLE; DEEP VEIN THROMBOSIS; DOSING ALGORITHM; DRUG MEGADOSE; DRUG RESISTANCE; DRUG SENSITIVITY; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; ITALY; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT DURATION; VALIDATION PROCESS; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1 GENE;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ETHNIC GROUPS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN; YOUNG ADULT;

EID: 84866493944     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1226-5     Document Type: Article

References (25)

1. Tan GM, Wu E, Lam YY, Yan BP (2010) Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics 11(3):439-448. doi:10.2217/pgs.10.8.
2. Lazo-Langner A, Kovacs MJ (2010) Predicting warfarin dose. Curr Opin Pulm Med 16(5):426-431. doi:10.1097/MCP. 0b013e32833b1c6c.
3. Sasaki T, Tabuchi H, Higuchi S, Ieiri I (2009) Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. Pharmacogenomics 10 (8):1257-1266. doi:10.2217/pgs.09.65.
4. Hirsh J (1991) Oral anticoagulant drugs. N Engl J Med 324 (26):1865-1875. doi:10.1056/NEJM199106273242606.
5. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage BF (2010) Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 87(5):572-578. doi:10.1038/clpt. 2010.13.
6. Roper N, Storer B, Bona R, Fang M (2010) Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn 12(3):283- 291. doi:10.2353/jmoldx.2010. 090110.
7. Becquemont L (2008) Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. Eur J Clin Pharmacol 64(10):953-960.
8. Limdi NA, Veenstra DL (2008) Warfarin pharmacogenetics. Pharmacotherapy 28(9):1084-1097.
9. Wells PS, Holbrook AM, Crowther NR, Hirsh J (1994) Interactions of warfarin with drugs and food. Ann Intern Med 121(9): 676-683.
10. Rieder MJ, Reiner AP, Rettie AE (2007) Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost 5(11):2227-2234. doi:10.1111/j.1538-7836.2007.02744.x.
11. Geisen C, WatzkaM, Sittinger K, Steffens M, Daugela L, Seifried E, Muller CR, Wienker TF, Oldenburg J (2005) VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94(4):773-779.
12. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22):2563-2570.
13. Pavani A, Naushad SM, Rupasree Y, Kumar TR, Malempati AR, Pinjala RK, Mishra RC, Kutala VK (2011) Optimization of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogen J. doi:10.1038/tpj.2011.4.
14. Gage BF, Lesko LJ (2008) Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 25(1):45-51.
15. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360(8):753-764. doi:10.1056/NEJMoa0809329.
16. Perini JA, Struchiner CJ, Silva-Assuncao E, Santana IS, Rangel F, Ojopi EB, Dias-Neto E, Suarez-Kurtz G (2008) Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther 84(6):722-728.
17. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7):2329-2333. doi:10.1182/blood- 2005-03-1108.
18. Schelleman H, Chen J, Chen Z, Christie J, Newcomb CW, Brensinger CM, Price M, Whitehead AS, Kealey C, Thorn CF, Samaha FF, Kimmel SE (2008) Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther 84(3):332-339. doi:10.1038/clpt.2008.101.
19. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4):784-792.
20. Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr, Linder MW (2007) Estimation of warfarin maintenance dose based on VKORC1 (-1639 G > A) and CYP2C9 genotypes. Clin Chem 53(7):1199-1205. doi:10.1373/clinchem. 2006.078139.
21. Zambon CF, Pengo V, Padrini R, Basso D, Schiavon S, Fogar P, Nisi A, Frigo AC, Moz S, Pelloso M, Plebani M (2011) VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics 12(1):15- 25. doi:10.2217/pgs.10.162.
22. Absher RK, Moore ME, Parker MH (2002) Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 36 (10):1512-1517.
23. Smith PJ, Hurlen M, Abdelnoor M, Arnesen H (2008) Less benefit from warfarin in diabetics after myocardial infarction? Cardiology 111(3):161-166. doi:10.1159/000121598.
24. Smith P, Arnesen H, Abdelnoor M (1992) Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction. Arch Intern Med 152(5):993-997.
25. van Bergen PF, Deckers JW, Jonker JJ, van Domburg RT, Azar AJ, Hofman A (1995) Efficacy of long-term anticoagulant treatment in subgroups of patients after myocardial infarction. Br Heart J 74 (2):117-121.